DE69210737D1 - Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen - Google Patents

Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen

Info

Publication number
DE69210737D1
DE69210737D1 DE69210737T DE69210737T DE69210737D1 DE 69210737 D1 DE69210737 D1 DE 69210737D1 DE 69210737 T DE69210737 T DE 69210737T DE 69210737 T DE69210737 T DE 69210737T DE 69210737 D1 DE69210737 D1 DE 69210737D1
Authority
DE
Germany
Prior art keywords
medicament
oxothiazolidine
treatment
carboxylates
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69210737T
Other languages
English (en)
Other versions
DE69210737T2 (de
Inventor
Dennis I Goldberg
David A Mark
W Bruce Rowe
Kathleen A Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transcend Therapeutics Inc
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Publication of DE69210737D1 publication Critical patent/DE69210737D1/de
Application granted granted Critical
Publication of DE69210737T2 publication Critical patent/DE69210737T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
DE69210737T 1991-09-30 1992-09-03 Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen Expired - Fee Related DE69210737T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76919491A 1991-09-30 1991-09-30

Publications (2)

Publication Number Publication Date
DE69210737D1 true DE69210737D1 (de) 1996-06-20
DE69210737T2 DE69210737T2 (de) 1996-10-02

Family

ID=25084740

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69210737T Expired - Fee Related DE69210737T2 (de) 1991-09-30 1992-09-03 Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen

Country Status (6)

Country Link
EP (1) EP0535390B1 (de)
JP (1) JPH05194269A (de)
AT (1) ATE137968T1 (de)
AU (1) AU655835B2 (de)
CA (1) CA2077966A1 (de)
DE (1) DE69210737T2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
WO1998030228A1 (en) * 1997-01-13 1998-07-16 Emory University Compounds and their combinations for the treatment of influenza infection
US20100216116A1 (en) * 2007-06-08 2010-08-26 Ghent University Viral latency model

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
AU661379B2 (en) * 1992-04-23 1995-07-20 Transcend Therapeutics, Inc Method of reducing or preventing toxicity associated with antiretroviral therapy

Also Published As

Publication number Publication date
JPH05194269A (ja) 1993-08-03
EP0535390B1 (de) 1996-05-15
CA2077966A1 (en) 1993-03-31
ATE137968T1 (de) 1996-06-15
AU2211592A (en) 1993-04-29
EP0535390A1 (de) 1993-04-07
AU655835B2 (en) 1995-01-12
DE69210737T2 (de) 1996-10-02

Similar Documents

Publication Publication Date Title
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69528751D1 (de) Verwendung von Interferon-alpha 8 subtype zur Herstellung von Medikamenten zur Behandlung von Viralinfektionen der Leber
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
ATE73663T1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
HK45193A (en) Ozone decontamination of blood and blood products
DE3881299D1 (de) Retinoide zur behandlung lichtgeschaedigter haut.
BR0009267A (pt) Tratamento da hepatite c com o uso da hipertermia
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
HU9201986D0 (en) A blood preparation inactivated to viruses
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
EP0733361A3 (de) Verfahren zur Inaktivierung eingehüllter Viren und Spermien
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ES2066914T3 (es) Factores a1, a2, a3 y h del antibiotico ge 2270.
ATE59778T1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
DE69210737T2 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE174507T1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
EP0342565A3 (de) Verwendung des Thiazol-Derivates Tiprotimod zur Herstellung eines Mittels zur Therapie von Virusinfektionen
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
DE59107405D1 (de) Ein Imidazobenzodiazepin zur Behandlung von Schlafstörungen
ATE237616T1 (de) Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv
DE69006187T2 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee